Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
Open Access
- 1 November 2020
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (11), 1478-1484
- https://doi.org/10.1136/annrheumdis-2020-217331
Abstract
Objectives To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Methods In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib 150 mg two times per day or placebo. To manage adverse events, treatment could be interrupted or the dose reduced to 100 mg two times per day. We assessed adverse events and dose adjustments over 52 weeks. Results A total of 576 patients received nintedanib (n=288) or placebo (n=288). The most common adverse event was diarrhoea, reported in 75.7% of patients in the nintedanib group and 31.6% in the placebo group; diarrhoea led to permanent treatment discontinuation in 6.9% and 0.3% of patients in the nintedanib and placebo groups, respectively. In the nintedanib and placebo groups, respectively, 48.3% and 12.2% of patients had >= 1 dose reduction and/or treatment interruption, and adverse events led to permanent discontinuation of the trial drug in 16.0% and 8.7% of patients. The adverse events associated with nintedanib were similar across subgroups defined by age, sex, race and weight. The rate of decline in forced vital capacity in patients treated with nintedanib was similar irrespective of dose adjustments. Conclusions The adverse event profile of nintedanib in patients with SSc-ILD is consistent with its established safety and tolerability profile in patients with idiopathic pulmonary fibrosis. Dose adjustment is important to minimise the impact of adverse events and help patients remain on therapy.Funding Information
- The SENSCIS trial was funded by Boehringer Ingelheim.
This publication has 17 references indexed in Scilit:
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesThe New England Journal of Medicine, 2019
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseThe New England Journal of Medicine, 2019
- Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trialsBMJ Open Respiratory Research, 2019
- Gastrointestinal involvement in systemic sclerosis: diagnosis and managementCurrent Opinion in Rheumatology, 2018
- Mapping and predicting mortality from systemic sclerosisAnnals Of The Rheumatic Diseases, 2017
- Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosisRespiratory Research, 2015
- Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic ReviewPLOS ONE, 2015
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2015
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2014
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals Of The Rheumatic Diseases, 2013